Mantle cell lymphoma - novel therapeutic options

被引：0

作者：

Domanska-Czyz, Katarzyna ^{[1
]}

机构：

[1] Oddzial Intensywnej Opieki Hematoonkol Warzawie, Klin Nowotworow Ukladu Chlonnego, Warsaw, Poland

来源：

ONCOLOGY IN CLINICAL PRACTICE | 2005年 / 1卷 / 02期

关键词：

mantle cell lymphoma; induction chemotherapy; high-dose chemotherapy and stem cell transplantation; maintenance therapy; rituximab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mantle cell lymphoma is associated with the worst prognosis among malignant lymphomas. Standard chemotherapy is not effective and median survival of 5 years is about 25%. Intensified induction regimens lead to higher initial response rate, but the overall survival is unchanged. Induction chemotherapy combined with rituximab may prolong time to progression and overall survival. High dose chemotherapy followed by autologous stem cell transplantation in first remission is associated with the best disease free and overall survival reported to date. Among available treatment options high dose chemotherapy should be considered standard approach in young patients. However its definite role should be confirmed in randomized clinical trials. In addition the role of molecular remission and maintenance therapy with monoclonal antibodies should be established.

引用

页码：96 / 108

页数：13

共 72 条

[1] Primary treatment with autologous stem cell transplantation in mantle cell lymphoma:: outcome related to remission pretransplant [J].

Andersen, NS ;

Pedersen, L ;

Elonen, E ;

Johnson, A ;

Kolstad, A ;

Franssila, K ;

Langholm, R ;

Ralfkiær, E ;

Åkerman, M ;

Eriksson, M ;

Kuittinen, O ;

Geisler, CH .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 71 (02) :73-80

[2] Mantle cell lymphoma: A clinicopathologic study of 80 cases [J].

Argatoff, LH ;

Connors, JM ;

Klasa, RJ ;

Horsman, DE ;

Gascoyne, RD .

BLOOD, 1997, 89 (06) :2067-2078

[3]

Assouline S, 2003, BLOOD, V102, p902A

[4] RETRACTED: High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support - Results of a pilot study (Retracted Article) [J].

Behr, TM ;

Griesinger, F ;

Riggert, J ;

Gratz, S ;

Béhé, M ;

Kaufmann, CC ;

Wörmann, B ;

Brittinger, G ;

Becker, W .

CANCER, 2002, 94 (04) :1363-1372

[5] Blastic variant of mantle cell lymphoma:: a rare but highly aggressive subtype [J].

Bernard, M ;

Gressin, R ;

Lefrère, F ;

Drénou, B ;

Branger, B ;

Caulet-Maugendre, S ;

Tass, P ;

Brousse, N ;

Valensi, F ;

Milpied, N ;

Voilat, L ;

Sadoun, A ;

Ghandour, C ;

Hunault, M ;

Leloup, R ;

Mannone, L ;

Hermine, O ;

Lamy, T .

LEUKEMIA, 2001, 15 (11) :1785-1791

[6]

Bosch F, 1998, CANCER, V82, P567, DOI 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO

[7]

2-Z

[8]

Brugger W, 2002, BLOOD, V100, p644A

[9] Phosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma [J].

Cohen, BJ ;

Moskowitz, C ;

Straus, D ;

Noy, A ;

Hedrick, E ;

Zelenetz, A .

LEUKEMIA & LYMPHOMA, 2001, 42 (05) :1015-+

[10]

Conde E, 2002, BLOOD, V100, p643A

← 1 2 3 4 5 6 7 8 →